ZVRA
Zevra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.40
−1.12%Year over year
Reported trailing growth
- Revenue
- +119.4%
- EBITDA
- +100.3%
- EBIT
- +132.8%
- EPS
- +1775.9%
- Free cash flow
- +170.1%
- Operating cash flow
- +172.3%
Forward estimates
Based on analyst estimates
- Revenue
- +19.3%
- EBITDA
- -0.8%
- EPS
- -11.1%
Three-year CAGR
- Revenue
- +118.8%
- EBITDA
- +229.2%
- EBIT
- +95.1%
- Net income
- +178.9%
- EPS
- +161.4%
- Free cash flow
- +96.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026